smv3.ch contributes to the development of Novaremed’s candidate drug NRD135S.E1 (Nispomeben®) by setting up and managing DMPK activities together with partner PKI. Our project is approaching an important milestone, the readout of our Phase 2b study:
The study evaluates Novaremed’s non-opioid investigational drug NRD.E1 (Nispomeben®) for the treatment of chronic pain associated with diabetic peripheral neuropathy, and is funded by the NIH Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative. Topline Phase 2b data readout is expected in Q4 2025.
The Phase 2b study is a 12-week, multicenter, randomized, double-blind, placebo-controlled clinical trial with the primary objective to demonstrate that a once daily dose of NRD.E1 80 mg is superior to placebo in relieving chronic pain among patients with painful diabetic peripheral neuropathy. The study will further assess safety, tolerability, pharmacokinetics, and the compound’s impact on sleep and quality of life. Study completion, with the last patient’s last visit (LPLV), is anticipated in Q3 2025 and the topline results are expected in December 2025.
Read more under https://www.novaremed.com